These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28964649)

  • 1. Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes.
    Kapoor S
    J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):3031. PubMed ID: 28964649
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 3. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.
    Halperin I; Morelli M; Korczyn AD; Youdim MB; Mandel SA
    Neurotherapeutics; 2009 Jan; 6(1):128-40. PubMed ID: 19110204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 6. ALS lessons learned from other neurological diseases. Parkinson's disease.
    Fahn S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

  • 10. Polyphenols in Parkinson's Disease: A Systematic Review of In Vivo Studies.
    Kujawska M; Jodynis-Liebert J
    Nutrients; 2018 May; 10(5):. PubMed ID: 29783725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatments in the early stage of Parkinson disease].
    Rascol O
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract]   [Full Text] [Related]  

  • 13. Insidious dopamine: provocateur or protective agent in Parkinson's disease?
    Kostrzewa RM; Brus R; Kostrzewa JP
    Pol J Pharmacol; 2001; 53(2):165-6. PubMed ID: 11787956
    [No Abstract]   [Full Text] [Related]  

  • 14. Movement disorders: understanding clinical trials.
    Goetz CG
    Lancet Neurol; 2005 Jan; 4(1):5-6. PubMed ID: 15620847
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
    CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial.
    Garcia Ruiz PJ
    Neurologist; 2011 Nov; 17(6 Suppl 1):S1. PubMed ID: 22045319
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible neuroprotective therapy for Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10 commonly asked questions about Parkinson disease.
    Bhidayasiri R; Brenden N
    Neurologist; 2011 Jan; 17(1):57-62. PubMed ID: 21192198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.